Under the Paperwork Reduction Act of 1995, no persons are required to

INFORMATION DISCLOSURE
STATEMENT BY APPLICANT
( Not for submission under 37 CFR 1.99)

Application Number		10564584
Filing Date		2006-01-13
First Named Inventor Klaus		Biester
Art Unit		3746
Examiner Name		
Attorney Docket Number		1600-13500 DAR

U.S. PATENTS						Remove			
			Kind Code <sup>1</sup>			Pages,Columns,Lines where Relevant Passages or Relevan Figures Appear			
	1	4276003		1981-06-30	Perkins et al.				
	2	5358035		2007-01-05	Grudzinski				
If you wis	h to a	dd additional U.S. Pate	nt citatio	n information p	lease click the	Add button.	_	Add	
			U.S.P	ATENT APPLI	CATION PUB	LICATIONS		Remove	
Examiner Initial*	Cite No	Publication Number	Kind Code <sup>1</sup>	Publication Date			Releva	,Columns,Lines where ant Passages or Rele s Appear	
	1								
If you wis	h to a	dd additional U.S. Pub	lished Ap	FOREIGN PA			d button	Add	
	_			FOREIGN PA	ENT DOCUM	MENTS			
Examiner Initial*	Cite No	Foreign Document Number <sup>3</sup>	Country Code <sup>2</sup>		Publication Date	Name of Patente Applicant of cited Document	e or	Pages,Columns,Line where Relevant Passages or Relevar Figures Appear	76
	1	WO9508860	wo		1995-03-30	Erhart			
	2	WO2005111484	wo		2005-11-24	Biester			

## INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)

Application Number		10564584		
Filing Date		2006-01-13		
First Named Inventor Klaus		Biester		
Art Unit		3746		
Examiner Name				
Attorney Docket Number		1600-13500 DAR		

	3	433649	€P		1991-07-26	Askoli			
	4	19880317	DE		1999-06-17	Karasawa			
	5	19955080	DE		2001-05-17	Weller			
	6	2038369	DE		1971-06-03	Bauereiss			
	7	2011402	DE		1971-09-23	Erfinder			
	8	WO0165061	wo		2001-09-07	Vinegar			
If you wis	h to a	d additional Foreign P	atent Document	citation	information pl	ease click the Add buttor	Add	$\vdash$	
			NON-PATEN	IT LITE	RATURE DO	CUMENTS	Remove		
Examiner Cite Initials* Cite Cook, and a serial symposium, catalog, etc), date, pages(s), volume-issue number(s), pulsar symposium, catalog, etc), date, pages(s), volume-issue number(s), pulsilaer, city and/or country where published.								T6	
	1	International Search Report for Appl. No. PCT/EP/2004/007948 dated 2004-02-12; (3 p.)							
	2 Examination Report for Appl. No. GB0603045.6 dated 2006-06-26 (2 p.)								
If you wish to add additional non-natent literature document citation information please click the Add hutton Add									

# | Application Number | 10564584 | Filing Date | 2006-01-13 | Filing Date |

EXAMINER SIGNATURE						
Examiner Signature		Date Considered				
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line th citation if not in conformance and not considered. Include copy of this form with next communication to applicant.						

16e Kin Codes of USPTO Patert Documents at www.USPTO.GOV or MPEP 801.04. 2 Enter office that issued the document, by the hov-letter code (WIPO Standard S13.) 3 "For implance patent for comments, the included on the year of the import on many precise the serial runty for patent document, and occurrently the appropriate symbols as indicated on the document under WIPO Standard S1.16 if possible. <sup>9</sup> Applicant is to place a check mark here if English languages translation to statistics.

### INFORMATION DISCLOSURE STATEMENT BY APPLICANT ( Not for submission under 37 CFR 1.99)

			10564584		
			2006-01-13		
		Klaus	Biester		
Art Unit			3746		
Examiner Name Attorney Docket Number					
		er	1600-13500 DAR		

#### CERTIFICATION STATEMENT

Please see 37 CFR 1.97 and 1.98 to make the appropriate selection(s):

That each item of information contained in the information disclosure statement was first cited in any communication from a foreign patient office in a counterpart foreign application not more than three months prior to the filling of the information disclosure statement. See 37 CFR 137(e)(1).

#### OR

That no item of information contained in the information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the person signing the certification after making reasonable inquity, no item of information contained in the information disclosure statement was known to any individual designated in 37 CFR 175(c) more than three months prior to the filing of the information disclosure statement. See 37 CFR 179(c).

- See attached certification statement.
- Fee set forth in 37 CFR 1.17 (p) has been submitted herewith.

#### SIGNATURE

A signature of the applicant or representative is required in accordance with CFR 1.33, 10.18. Please see CFR 1.4(d) for the form of the signature.

Signature	/David A. Rose/	Date (YYYY-MM-DD)	2007-01-22
Name/Print	David A. Rose	Registration Number	26 223

This collection of information is required by 3T CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is for lie fand by the USPTO to process) an application. Confidentiality is governed by \$5 U.S. C. 12.0 and 3T CFR 1.14. This collection is estimated to take 1 hour to complete, including gathering, preparing and submitting the completed application from the USPTO. Time will vary depending upon the individual case: Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. operatment of Commence, P.O. 8bx 1449, Alexandriv, V.S. 2311-1450, D.O. NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. 8bx 1459, Alexandriva, V.S. 2311-1450.

#### Privacy Act Statement

The Privacy Act of 1974 (P. L. 93-579) requires that you be given certain information in connection with your submission of the stackhold from related to a patient application or patient. Accordingly, pursuant to the requirements of the Act, places be advised that (1) the general authority for the collection of this information is 35 U.S.C. 2(b)(2); (2) familishing of the information solicided is couldrain; and (3) the primoral pursuance for which the information is used by the U.S. Patient and Trademan Coffice is to process and/or examine your submission related to a patient agricultant or patient. If you do not furnish the requested process and/or examine your submission related to a patient agricultant or patient. If you do not furnish the requested results of the patient of the patient and the patient of the patient

The information provided by you in this form will be subject to the following routine uses:

- The information on this form will be treated confidentially to the extent allowed under the Freedom of Information Act (5 U.S.C. 552) and the Privacy Act (5 U.S.C. 552a). Records from this system of records may be disclosed to the Department of Justice to determine whether the Freedom of Information Act requires disclosure of these record s.
  - A record from this system of records may be disclosed, as a routine use, in the course of presenting evidence to a court, magistrate, or administrative tribunal, including disclosures to opposing counsel in the course of settlement negotiation.
  - A record in this system of records may be disclosed, as a routine use, to a Member of Congress submitting a request involving an individual, to whom the record pertains, when the individual has requested assistance from the Member with respect to the subject matter of the record.
  - A record in this system of records may be disclosed, as a routine use, to a contractor of the Agency having need for the information in order to perform a contract. Recipients of information shall be required to comply with the requirements of the Privacy Act of 1974, as amended, pursuant to 5 U.S.C. 552(m).
  - A record related to an International Application filed under the Patent Cooperation Treaty in this system of records
    may be disclosed, as a routine use, to the International Bureau of the World Intellectual Property Organization, pursuant
    to the Patent Cooperation Treaty.
  - A record in this system of records may be disclosed, as a routine use, to another federal agency for purposes of National Security review (35 U.S.C. 181) and for review pursuant to the Atomic Energy Act (42 U.S.C. 218(c)).
  - 7. A record from this system of records may be disclosed, as a routine use, to the Administrator, General Services, or hisher designed, uturing an insection of records conducted by GSA as part of that agency's responsibility to recommend improvements in records management practices and programs, under authority of 4d U.S.C. 2904 and 2905. Such disclosure shall be made in accordance with the GSA requisions governing inseption of records for this purpose, and any other relevant (i.e., GSA or Commerce) directive. Such disclosure shall not be used to make determinations about individuals.
- A record from this system of records may be disclosed, as a routine use, to the public after either publication of the
  application pursuant to 35 U.S.C. 12(2) to rissuance of a patent pursuant to 35 U.S.C. 151. Further, a record may be
  disclosed, subject to the limitations of 37 CFR 1.14, as a routine use, to the public if the record was filled in application
  which became abandoned or in which the proceedings were terminated and which application is referenced by either a
  published application, an application open to public inspections or as issued patent.
  - A record from this system of records may be disclosed, as a routine use, to a Federal, State, or local law enforcement agency, if the USPTO becomes aware of a violation or potential violation of law or regulation.